127 related articles for article (PubMed ID: 16711515)
1. Chromogranin A blood concentrations in relation to those of prolactin in hormone-refractory metastatic prostate cancer: possible existence of two independent mechanisms responsible for endocrine resistance.
Lissoni P; Viganò P; Podraska A; Brivio R; Colciago M; Casu M; Manganini V; Giuberti C; Strada G; Gardani G
Int J Biol Markers; 2006; 21(1):58-9. PubMed ID: 16711515
[No Abstract] [Full Text] [Related]
2. Possible involvement of prolactin in endocrine-resistant metastatic prostate cancer.
Lissoni P; Bignami A; Frontini L; Manganini V; Dapretto E; Gardani GS; Viganò P; Strada G
Int J Biol Markers; 2005; 20(2):123-5. PubMed ID: 16011043
[TBL] [Abstract][Full Text] [Related]
3. Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease.
Berruti A; Mosca A; Tucci M; Terrone C; Torta M; Tarabuzzi R; Russo L; Cracco C; Bollito E; Scarpa RM; Angeli A; Dogliotti L
Endocr Relat Cancer; 2005 Mar; 12(1):109-17. PubMed ID: 15788643
[TBL] [Abstract][Full Text] [Related]
4. Elevated plasma chromogranin-A concentrations in prostatic carcinoma.
Kadmon D; Thompson TC; Lynch GR; Scardino PT
J Urol; 1991 Aug; 146(2):358-61. PubMed ID: 1856931
[TBL] [Abstract][Full Text] [Related]
5. [Serum chromogranin A in prostate cancer. Preliminary results].
Reale MG; Marchei GG; Boccia S; Cristofoletti C; Caporossi E; Marchei M; Izzo P; Marchei P
Minerva Med; 1999; 90(7-8):221-3. PubMed ID: 10719423
[No Abstract] [Full Text] [Related]
6. Serum chromogranin-A in advanced prostate cancer.
Ferrero-Poüs M; Hersant AM; Pecking A; Brésard-Leroy M; Pichon MF
BJU Int; 2001 Nov; 88(7):790-6. PubMed ID: 11890255
[TBL] [Abstract][Full Text] [Related]
7. A phase II study of tamoxifen in hormone-resistant metastatic prostate cancer: possible relation with prolactin secretion.
Lissoni P; Vigano P; Vaghi M; Frontini L; Giuberti C; Manganini V; Casu M; Brivio F; Niespolo R; Strada G
Anticancer Res; 2005; 25(5):3597-9. PubMed ID: 16101186
[TBL] [Abstract][Full Text] [Related]
8. A new PTP parameter as potential predictor of prostate cancer response to therapy.
Tarle M
Int J Rad Appl Instrum B; 1988; 15(2):225-7. PubMed ID: 3366623
[TBL] [Abstract][Full Text] [Related]
9. Variation in chromogranin A serum levels during intermittent versus continuous androgen deprivation therapy for prostate adenocarcinoma.
Sciarra A; Monti S; Gentile V; Mariotti G; Cardi A; Voria G; Lucera R; Di Silverio F
Prostate; 2003 May; 55(3):168-79. PubMed ID: 12692782
[TBL] [Abstract][Full Text] [Related]
10. Circulating neuroendocrine markers in patients with prostate carcinoma.
Berruti A; Dogliotti L; Mosca A; Bellina M; Mari M; Torta M; Tarabuzzi R; Bollito E; Fontana D; Angeli A
Cancer; 2000 Jun; 88(11):2590-7. PubMed ID: 10861438
[TBL] [Abstract][Full Text] [Related]
11. Effect of nonsteroidal antiandrogen monotherapy versus castration therapy on neuroendocrine differentiation in prostate carcinoma.
Sciarra A; Di Silverio F
Urology; 2004 Mar; 63(3):523-7. PubMed ID: 15028450
[TBL] [Abstract][Full Text] [Related]
12. Neuroendocrine differentiation in prostate cancer: is it detectable and treatable?
Birtle AJ; Freeman A; Payne HA; Masters JR; Harland SJ
BJU Int; 2003 Sep; 92(4):490. PubMed ID: 12930449
[No Abstract] [Full Text] [Related]
13. Changes in chromogranin a serum levels during endocrine therapy in metastatic prostate cancer patients.
Sasaki T; Komiya A; Suzuki H; Shimbo M; Ueda T; Akakura K; Ichikawa T
Eur Urol; 2005 Aug; 48(2):224-9; discussion 229-30. PubMed ID: 16005374
[TBL] [Abstract][Full Text] [Related]
14. Development of an ELISA for the detection of serum chromogranin A (CgA) in prostate and non-neuroendocrine carcinomas.
Tsao KC; Wu JT
Clin Chim Acta; 2001 Nov; 313(1-2):21-9. PubMed ID: 11694235
[TBL] [Abstract][Full Text] [Related]
15. Elevated serum chromogranin A precedes prostate-specific antigen elevation and predicts failure of androgen deprivation therapy in patients with advanced prostate cancer.
Chuang CK; Wu TL; Tsao KC; Liao SK
J Formos Med Assoc; 2003 Jul; 102(7):480-5. PubMed ID: 14517586
[TBL] [Abstract][Full Text] [Related]
16. Oral estramustine therapy in serum chromogranin A-positive stage D3 prostate cancer patients.
Zaky Ahel M; Kovacic K; Kraljic I; Tarle M
Anticancer Res; 2001; 21(2B):1475-9. PubMed ID: 11396235
[TBL] [Abstract][Full Text] [Related]
17. Plasma chromogranin A in prostatic carcinoma and neuroendocrine tumors.
Kimura N; Hoshi S; Takahashi M; Takeha S; Shizawa S; Nagura H
J Urol; 1997 Feb; 157(2):565-8. PubMed ID: 8996358
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study.
Taplin ME; George DJ; Halabi S; Sanford B; Febbo PG; Hennessy KT; Mihos CG; Vogelzang NJ; Small EJ; Kantoff PW
Urology; 2005 Aug; 66(2):386-91. PubMed ID: 16098367
[TBL] [Abstract][Full Text] [Related]
19. Re: Chromogranin A concentration as a serum marker to predict prognosis after endocrine therapy for prostate cancer.
Yashi M; Tokue A
J Urol; 2003 Jun; 169(6):2305; author reply 2305. PubMed ID: 12771784
[No Abstract] [Full Text] [Related]
20. [Plasma chromogranin-A (CgA)--a potential marker for diagnosis, monitoring and management of prostate cancer patients].
Leibovitch I; Pinthus Y; Sella BA; Ramon J
Harefuah; 2006 Jan; 145(1):25-9, 78. PubMed ID: 16450720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
